



THE ART *and* SCIENCE

of Managing the New Melanoma Landscape

6th Annual Collaborative Conference

**Friday, October 22 -
Saturday, October 23, 2027**

Houston Marriott Medical Center
6580 Fannin Street
Houston, Texas

THE UNIVERSITY OF TEXAS
**MDAnderson
Cancer Center**
Making Cancer History®





Focus

The diagnosis, prognosis, and management of patients with melanoma and non-melanoma skin cancers are evolving rapidly due to new understanding, guidelines, and regulatory approvals. Due to these changes, there are many areas of need for physician education in order to optimize the care of patients with these diseases. Thus, this educational activity will reach clinicians in both the academic and community clinical settings to raise the level of knowledge about current and emerging treatment options for patients with melanoma and non-melanoma skin cancers.

The University of Texas MD Anderson Cancer Center will develop a high-quality educational activity that is designed to overcome barriers to optimized patient care in the rapidly changing landscape of melanoma and non-melanoma skin cancers. To address the performance gaps, educational needs, and subsequent learning objectives, we recommend support for the development and execution of a national educational conference. MD Anderson has selected this live event, which will be multi-topic and multi-supported, as the foundation for an educational initiative that will provide an environment conducive to engagement and dialogue with peers and presenters. The initiative is anticipated to increase understanding and competency through expert presentations and related panel discussion on representative clinical cases.

The conference will be comprised of multiple sessions led by national experts in melanoma and non-melanoma skin cancer. With the focus on multidisciplinary management, the scientific agenda will be comprehensive and effective in addressing the educational needs of the target audience of clinicians and caregivers. It will also address the importance of multidisciplinary communications and management strategies for pre-clinical and clinical management along the disease continuum.





Educational Objectives

After attending the conference, participants should be able to:

- Utilize the latest criteria and clinical evidence for treatment options for melanoma patients with clinically localized disease and interpret the components of the updated AJCC staging system for melanoma (*Knowledge, Competence, Performance, Patient Outcomes*);
- Make evidence-based decisions about the use of adjuvant immune and targeted therapies in patients with surgically resected stage III disease (*Knowledge, Competence, Performance, Patient Outcomes*);
- Make evidence-based decisions about the optimal selection and use of immunotherapy and targeted therapy in patients with stage IV metastatic disease (*Knowledge, Competence, Performance, Patient Outcomes*);
- Understand how to diagnose and treat toxicities from current systemic therapies for advanced melanoma patients (*Knowledge*);
- Understand the current data about the role of different treatment modalities, including immune and targeted therapies, in patients with brain metastases and with non-cutaneous melanomas (*Knowledge*);
- Understand the current data about the role of immunotherapy in the management of patients with non-melanoma skin cancer, including cutaneous squamous cell carcinoma and Merkel cell carcinoma (*Knowledge*).

Educational Methods

Lecture/Didactic • Case Study • Audience Response System • Panel Discussion

Target Audience

This conference should be of value to medical oncologists, surgical oncologists, dermatologists, nurse practitioners, scientists/researchers and other healthcare providers managing patients with melanoma.

Evaluation

A conference evaluation link will be included in the final program. This online survey will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

Accreditation/Credit Designation

Physicians

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 10.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Certificates and Attendance Verification Certificates

Certificates awarding *AMA PRA Category 1 Credits™* or certificates documenting attendance will be emailed when an individual completes the online CME Verification process.

Presentations

WILL BE AVAILABLE AFTER THE CONFERENCE

All of the PowerPoint presentations will be posted online after the conference. You will receive an invitation email from **Study@MD Anderson** to create a username and password to log into Study. If you do not receive this instructional email by October 4, please email ambaring@mdanderson.org.

MD Anderson Planning Committee

Michael A. Davies, MD, PhD (Co-Chair)

Chair

Melanoma Medical Oncology

Patrick Hwu, MD (Co-Chair)

Division Head

Cancer Medicine

Merrick I. Ross, MD (Co-Chair)

Professor

Surgical Oncology

Michael K. Wong, MD, PhD (Co-Chair)

Professor

Melanoma Medical Oncology

Allison Baring, CMP

CME Conference Planner

CME/Conference

Management

CONFERENCE AGENDA

October 22, 2027

9:00 am Registration and Continental Breakfast

10:00 **Welcome**
Merrick I. Ross, MD

Session 1- Melanoma: Initial Diagnosis, Staging, and Surgical Management

10:05 **Introduction**
Merrick I. Ross, MD

10:10 **Improving Prognostic Models to Enhance Clinical Decision-Making in Melanoma**
Jeffrey E. Gershenwald, MD

10:35 **Melanoma Pathology and Biomarkers, 2027**
Michael Tetzlaff, MD, PhD

11:00 **Project ECHO: Telementoring to Optimize Early Melanoma Diagnosis**
Kelly C. Nelson, MD

11:30 **Surgical Management of Clinically Localized Disease**
Merrick I. Ross, MD

12:00 pm **Multidisciplinary Panel & Case Discussion**

12:40 **Summary**
Merrick I. Ross, MD

12:45 Lunch - Provided

Session 2- Integrating New Therapies in the Management of Regional Disease

1:30 **Opening Remarks**
Hussein Tawbi, MD, PhD

1:35 **Adjuvant Therapy: Many Options, Many Questions**
Hussein Tawbi, MD, PhD

2:05 **Neoadjuvant Therapy: New Data and Best Practices**
Rodabe N. Amaria, MD

2:35 **The Role of Intralesional Therapy in Melanoma (*No CME Credit)**
Robert H.I. Andtbacka, MD, CM

3:05 **Multidisciplinary Panel & Case Discussion**

3:45 **Summary**
Hussein Tawbi, MD, PhD

3:50 Break

Session 3- New Breakthroughs in Melanoma Research

4:10 **Opening Remarks**
Patrick Hwu, MD

4:15 **Combining Immune and Targeted Therapy: Rationale and Early Results**
Ryan J. Sullivan, MD

- 
- 4:50 **Breakthroughs in the Understanding & Treatment of Brain Metastases**
Michael A. Davies, MD, PhD
 - 5:25 **Summary**
Patrick Hwu, MD
 - 5:30 pm Adjourn and Reception

October 23, 2027

7:00 am Registration and Continental Breakfast

Session 4- Metastatic Melanoma: Optimizing Immune and Targeted Therapies

- 8:00 **Introduction**
Michael A. Davies, MD, PhD
- 8:05 **Immunotherapy for Metastatic Melanoma: Successes, Questions, and Controversies**
Michael A. Postow, MD
- 8:35 **Recognition and Management of Autoimmune Toxicities**
Isabella Glitza Oliva, MD, PhD
- 9:05 **What's New in Targeted Therapy for Melanoma**
Michael A. Davies, MD, PhD
- 9:35 **Multidisciplinary Panel & Case Discussion**
- 10:15 **Summary**
Michael A. Davies, MD, PhD
- 10:20 Break

Session 5- The Art of Melanoma Management

- 10:40 **Introduction**
Michael K. Wong, MD, PhD
- 10:45 **Multidisciplinary Management of Brain Metastases: The MD Anderson Brain Metastasis Clinic**
Hussein Tawbi, MD, PhD
- 11:15 **Diet and the Microbiome in Melanoma: What to Tell Your Patients**
Jennifer L. McQuade, MD
- 11:45 **New Advances and Investigations in Mucosal and Uveal Melanoma**
Sapna P. Patel, MD
- 12:15 pm **Breakthroughs for Non-Melanoma Skin Cancers**
Michael K. Wong, MD, PhD
- 12:45 **Multidisciplinary Panel & Case Discussion**
- 1:25 **Closing Remarks**
Michael A. Davies, MD, PhD; Patrick Hwu, MD; Merrick I. Ross, MD; Michael K. Wong, MD, PhD
- 1:30 pm Adjourn

MD Anderson Faculty

Rodabe N. Amaria, MD <i>Assistant Professor Melanoma Medical Oncology</i>	Patrick Hwu, MD (Co-Chair) <i>Division Head Cancer Medicine</i>	Merrick I. Ross, MD (Co-Chair) <i>Professor Surgical Oncology</i>
Michael A. Davies, MD, PhD (Co-Chair) <i>Chair Melanoma Medical Oncology</i>	Jennifer L. McQuade, MD <i>Assistant Professor Melanoma Medical Oncology</i>	Hussein Tawbi, MD, PhD <i>Associate Professor Melanoma Medical Oncology</i>
Jeffrey E. Gershenwald, MD <i>Professor Surgical Oncology</i>	Kelly C. Nelson, MD <i>Associate Professor Dermatology</i>	Michael Tetzlaff, MD, PhD <i>Associate Professor Pathology Administration</i>
Isabella Glitza Oliva, MD, PhD <i>Assistant Professor Melanoma Medical Oncology</i>	Sapna P. Patel, MD <i>Associate Professor Melanoma Medical Oncology</i>	Michael K. Wong, MD, PhD (Co-Chair) <i>Professor Melanoma Medical Oncology</i>

Guest Faculty

Robert H.I. Andtbacka, MD, CM <i>Chief Medical Officer Seven and Eight Biopharmaceuticals Inc. Edison, New Jersey</i>	Michael A. Postow, MD <i>Medical Oncologist Memorial Sloan Kettering Cancer Center New York City, New York</i>	Ryan J. Sullivan, MD <i>Assistant Professor Medicine Harvard Medical School Assistant Professor Hematology/Oncology Massachusetts General Hospital Boston, Massachusetts</i>
---	--	--

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, schedule conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.

The University of Texas MD Anderson Cancer Center does not endorse the commercial products, equipment, or services presented by program supporters/exhibitors.

Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or e-mail CME/Conference Management. All responses will be forwarded to the Program Chairs for consideration.

Registration Information

On-site registration opens at 9:00 am on Friday, October 22. Breakfast will be available. The Welcome and Introduction will begin at 10:00 am and the conference will adjourn at 1:30 pm on Saturday, October 23. Advanced registration is encouraged as space and materials are limited.

The deadline for advanced registration is Friday, September 24, 2027.

There are three ways to register:

1. Online at: www.mdanderson.org/conferences
2. Fax to: 713-794-1724
3. Mail to: CME/Conference Management – Unit 1781
The University of Texas MD Anderson Cancer Center
P.O. Box 301407
Houston, TX 77230-1407

We accept the following forms of payment:

- Check (payable through U.S. banks only)
- Money Order
- Credit Cards (MasterCard, VISA, and American Express)
- Cash (on-site registration only)

A receipt and confirmation letter will be sent to you within ten working days of receipt of your fee. The conference registration fee includes tuition, final conference agenda, continental breakfasts, breaks, lunch and reception. Please refer to the registration form for specific information regarding fees.

Refund/Cancellation Policy

The registration fee, minus a \$50 administrative handling fee, is refundable if a written request is received on or before **September 24, 2027**. No refunds will be granted after that date. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check.

CME/Conference Management reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or the contact numbers as given on the registration form. In case of activity cancellation, liability of CME/Conference Management is limited to the registration fee. CME/Conference Management will refund the full registration fee.

CME/Conference Management reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available.

For additional information, please contact CME/Conference Management at 713-792-2223 or toll free at 866-849-5866.

Special Assistance

Contact CME/Conference Management at 713-792-2223 or toll-free at 866-849-5866 if you have any special dietary or ADA accommodation needs.

Accommodations

- A block of rooms has been reserved for conference attendees at the **Houston Marriott Medical Center** located at 6580 Fannin Street, Houston, Texas.
- Early hotel reservation is suggested and the room block cutoff date is: **Thursday, September 23, 2027.**
- The hotel phone number is 1-800-228-9290.
- When you make reservations, be sure to mention the group name: **The Art and Science of Managing the New Melanoma Landscape** room block to be assured of receiving the special meeting rate of \$189 for a standard guest room. Please add 17% Texas state and local taxes.

Ground Transportation

(prices are subject to change and variable depending on location of conference)

- Houston is served by two airports, George Bush Intercontinental (IAH) and William P. Hobby (HOU). The following forms of ground transportation are available to and from both airports:
 - Uber or Lyft
 - Yellow Cab - 713-236-1111
 - Super Shuttle: For more information, call toll free at 800-258-3826 or visit www.supershuttle.com